Asset Details
Do you wish to reserve the book?
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Do you wish to request the book?
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
2016
Overview
This trial compared standard therapy (dual antiplatelet therapy plus a vitamin K antagonist) with two regimens containing rivaroxaban plus antiplatelet therapy. The rivaroxaban groups had reduced rates of bleeding and similar efficacy in preventing cardiovascular events.
Approximately 5 to 8% of patients who undergo percutaneous coronary intervention (PCI) have atrial fibrillation.
1
–
3
Dual antiplatelet therapy (DAPT) with a P2Y
12
inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent,
4
but oral anticoagulation is superior to DAPT in reducing the risk of ischemic stroke in patients with atrial fibrillation.
5
The treatment strategy for patients with atrial fibrillation who have received stents must balance the risk of stent thrombosis and ischemic stroke with the risk of bleeding. A common guideline-supported . . .
Publisher
Massachusetts Medical Society
Subject
/ Aspirin
/ Atrial Fibrillation - drug therapy
/ Atrial Fibrillation - therapy
/ Bleeding
/ Cardiovascular Diseases - epidemiology
/ Cardiovascular Diseases - mortality
/ Factor Xa Inhibitors - administration & dosage
/ Factor Xa Inhibitors - adverse effects
/ Female
/ Hemorrhage - chemically induced
/ Hemorrhage - prevention & control
/ Humans
/ Implants
/ Male
/ Percutaneous Coronary Intervention
/ Platelet Aggregation Inhibitors - adverse effects
/ Platelet Aggregation Inhibitors - therapeutic use
/ Purinergic P2Y Receptor Antagonists - adverse effects
/ Purinergic P2Y Receptor Antagonists - therapeutic use
/ Rivaroxaban - administration & dosage
/ Rivaroxaban - adverse effects
/ Stents
/ Stroke
